{"id":"https://openalex.org/W4387943866","doi":"https://doi.org/10.1016/j.mmifmc.2022.03.279","title":"Cabot\u00e9gravir + rilpivirine \u00e0 longue dur\u00e9e d'action tous les 2 mois : r\u00e9sultats d'ATLAS 2M \u00e0 152 semaines","display_name":"Cabot\u00e9gravir + rilpivirine \u00e0 longue dur\u00e9e d'action tous les 2 mois : r\u00e9sultats d'ATLAS 2M \u00e0 152 semaines","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4387943866","doi":"https://doi.org/10.1016/j.mmifmc.2022.03.279"},"language":"fr","primary_location":{"id":"doi:10.1016/j.mmifmc.2022.03.279","doi":"https://doi.org/10.1016/j.mmifmc.2022.03.279","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.mmifmc.2022.03.279","pdf_url":null,"source":{"id":"https://openalex.org/S4210197659","display_name":"M\u00e9decine et Maladies Infectieuses Formation","issn_l":"2772-7432","issn":["2772-7432","2772-7440"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"M\u00e9decine et Maladies Infectieuses Formation","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029233916","display_name":"Jacques Reynes","orcid":"https://orcid.org/0000-0002-5893-2789","observed_orcids":["https://orcid.org/0000-0002-5893-2789"]},"institutions":[{"id":"https://openalex.org/I4210093292","display_name":"Centre Hospitalier Universitaire de Montpellier","ror":"https://ror.org/00mthsf17","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210093292"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"J. Reynes","raw_affiliation_strings":["CHU Montpellier, Montpellier, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHU Montpellier, Montpellier, France","institution_ids":["https://openalex.org/I4210093292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013736817","display_name":"Edgar Turner Overton","orcid":"https://orcid.org/0000-0002-4013-536X","observed_orcids":["https://orcid.org/0000-0002-4013-536X"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. Overton","raw_affiliation_strings":["Universit\u00e9 d'Alabama, Birmingham, Etats-Unis"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e9 d'Alabama, Birmingham, Etats-Unis","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048101327","display_name":"Anders Thalme","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"A. Thalme","raw_affiliation_strings":["H\u00f4pital universitaire Karolinska, Stockholm, Su\u00e8de"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H\u00f4pital universitaire Karolinska, Stockholm, Su\u00e8de","institution_ids":["https://openalex.org/I1335113835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048076117","display_name":"Alexander Wong","orcid":"https://orcid.org/0009-0009-9781-5479","observed_orcids":["https://orcid.org/0009-0009-9781-5479"]},"institutions":[{"id":"https://openalex.org/I194028371","display_name":"University of Regina","ror":"https://ror.org/03dzc0485","country_code":"CA","type":"education","lineage":["https://openalex.org/I194028371"]},{"id":"https://openalex.org/I32625721","display_name":"University of Saskatchewan","ror":"https://ror.org/010x8gc63","country_code":"CA","type":"education","lineage":["https://openalex.org/I32625721"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"A. Wong","raw_affiliation_strings":["Universit\u00e9 de la Saskatchewan, Regina, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e9 de la Saskatchewan, Regina, Canada","institution_ids":["https://openalex.org/I194028371","https://openalex.org/I32625721"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020763663","display_name":"Norma Porteiro","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Porteiro","raw_affiliation_strings":["Fundacion IDEAA, Buenos Aires, Argentine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fundacion IDEAA, Buenos Aires, Argentine","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032114713","display_name":"Carlos Mart\u00edn Espa\u00f1ol","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"C. Espa\u00f1ol","raw_affiliation_strings":["GlaxoSmithKline, Brentford, Royaume-Uni","GlaxoSmithKline, Buenos Aires, Argentine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Brentford, Royaume-Uni","institution_ids":["https://openalex.org/I188950975"]},{"raw_affiliation_string":"GlaxoSmithKline, Buenos Aires, Argentine","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077601796","display_name":"Carolina Acuipil","orcid":"https://orcid.org/0009-0008-7672-3818","observed_orcids":["https://orcid.org/0009-0008-7672-3818"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"C. Acuipil","raw_affiliation_strings":["GlaxoSmithKline, Brentford, Royaume-Uni","GlaxoSmithKline, Buenos Aires, Argentine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Brentford, Royaume-Uni","institution_ids":["https://openalex.org/I188950975"]},{"raw_affiliation_string":"GlaxoSmithKline, Buenos Aires, Argentine","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103069452","display_name":"Ronald D. D'Amico","orcid":"https://orcid.org/0000-0003-0828-0222","observed_orcids":["https://orcid.org/0000-0003-0828-0222"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. D'amico","raw_affiliation_strings":["ViiV Healthcare, Research Triangle Park, Etats-Unis"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ViiV Healthcare, Research Triangle Park, Etats-Unis","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045218126","display_name":"Kati Vandermeulen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"K. Vandermeulen","raw_affiliation_strings":["Janssen Research & Development, Beerse, Belgique"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Beerse, Belgique","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044001938","display_name":"William R. Spreen","orcid":"https://orcid.org/0000-0002-8180-1517","observed_orcids":["https://orcid.org/0000-0002-8180-1517"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Spreen","raw_affiliation_strings":["ViiV Healthcare, Research Triangle Park, Etats-Unis"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ViiV Healthcare, Research Triangle Park, Etats-Unis","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"1","issue":"2","first_page":"S129","last_page":"S129"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.004900000058114529,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cabotegravir","display_name":"cabotegravir","score":0.9679999947547913},{"id":"https://openalex.org/keywords/rilpivirine","display_name":"rilpivirine","score":0.9950000047683716},{"id":"https://openalex.org/keywords/long-acting-antiretroviral-therapy","display_name":"long-acting antiretroviral therapy","score":0.8550000190734863},{"id":"https://openalex.org/keywords/hiv-1","display_name":"HIV-1","score":0.6200000047683716},{"id":"https://openalex.org/keywords/intramuscular-administration","display_name":"intramuscular administration","score":0.6779999732971191},{"id":"https://openalex.org/keywords/twice-weekly-dosing","display_name":"twice-weekly dosing","score":0.6629999876022339},{"id":"https://openalex.org/keywords/viral-suppression","display_name":"viral suppression","score":0.6389999985694885},{"id":"https://openalex.org/keywords/treatment-tolerability","display_name":"treatment tolerability","score":0.45899999141693115},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.8730000257492065},{"id":"https://openalex.org/keywords/people-who-inject-drugs","display_name":"people who inject drugs","score":0.44200000166893005}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7341904640197754},{"id":"https://openalex.org/C2778723075","wikidata":"https://www.wikidata.org/wiki/Q421547","display_name":"Rilpivirine","level":5,"score":0.5913830995559692},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.4892840087413788},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.44303250312805176},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.17668911814689636},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.06063130497932434},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.04880869388580322}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.mmifmc.2022.03.279","doi":"https://doi.org/10.1016/j.mmifmc.2022.03.279","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.mmifmc.2022.03.279","pdf_url":null,"source":{"id":"https://openalex.org/S4210197659","display_name":"M\u00e9decine et Maladies Infectieuses Formation","issn_l":"2772-7432","issn":["2772-7432","2772-7440"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"M\u00e9decine et Maladies Infectieuses Formation","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4399548861","https://openalex.org/W4317568027","https://openalex.org/W4387943827","https://openalex.org/W4200447938","https://openalex.org/W4376874522","https://openalex.org/W4311746946","https://openalex.org/W3115626280","https://openalex.org/W3118531265","https://openalex.org/W3206131309","https://openalex.org/W4376874466"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2023-10-26T00:00:00"}